ABITEC and Curapath Sign Strategic Memorandum of Understanding (MOU)to Advance Next-Generation LNP Delivery Technologies

ABITEC n and Curapath have signed a strategic MOU expand access to custom lipids, PEG-free shielding technologies, and lipid nanoparticle (LNP) formulation.

STOCKHOLM, SWEDEN, SWEDEN, September 17, 2026 /EINPresswire.com/ — ABITEC Corporation and Curapath have signed a strategic MOU expand access to high-purity custom lipids, PEG-free shielding technologies, and advanced lipid nanoparticle (LNP) formulation solutions.

The collaboration brings together ABITEC’s lipid chemistry and manufacturing expertise with Curapath’s PEG-free shielding polymer technologies and cGMP manufacturing capabilities, enabling developers to design more flexible, fit-for-purpose LNP delivery systems.

While PEG-lipids remain important in many LNP systems, repeat-dosing applications may benefit from alternative shielding approaches. Through this MOU, ABITEC and Curapath aim to give customers broader formulation options for vaccines, cell therapies, genetic medicines, and other advanced therapeutics.

“This collaboration directly addresses one of the key needs in LNP development: greater flexibility in lipid and shielding technologies,” said Dr. Donald Kelemen, Chief Scientific Officer of ABITEC. “By combining ABITEC’s high-purity custom lipids with Curapath’s PEG-free platform and manufacturing capabilities, we can help customers accelerate the successful development of next-generation therapeutics and vaccines.”

We are excited to collaborate with ABITEC, a company with a long-standing reputation for excellence in lipid science and manufacturing,” said Dr. Víctor R. de la Rosa, Commercial Product Manager at Curapath. “Drug developers today need integrated solutions to support complex therapeutic modalities. By combining our expertise in PEG-free shielding technologies, lipid excipients, nanoformulation, and cGMP manufacturing, we are expanding the toolbox available to innovators working across nucleic acid therapeutics, vaccines, cell therapies, biologics, and other next-generation medicines”

About ABITEC Corporation

ABITEC is a global leader in specialty lipids and surfactants, providing high-quality solutions for pharmaceutical, nutraceutical, personal care, food, and industrial applications. The company supports customers with deep technical, regulatory, formulation, and manufacturing expertise.

ABITEC is part of ABF Ingredients, a division of Associated British Foods, which brings together specialist ingredient businesses serving food, beverage, pharmaceutical, personal care, and industrial markets worldwide.

For further information, please contact Isabella Tillotson, Marketing Coordinator at ABITEC (ITillotson@abiteccorp.com).

To learn more about Abitec, please visit www.abiteccorp.com

About Curapath

Curapath is a science-driven CDMO specializing in the design, development, and GMP manufacturing of advanced drug delivery systems. The company supports biopharmaceutical partners from early research through commercial production, providing expertise across polymer and lipid chemistry, nanoformulation, and non-viral delivery technologies.

Leveraging proprietary polymer platforms, PEG-free shielding technologies, and advanced formulation capabilities, Curapath helps innovators address complex delivery challenges and accelerate the development of nucleic acid therapeutics, vaccines, biologics, and other next-generation medicines.

For further information, please contact Víctor R. de la Rosa, Commercial Product Manager at Curapath (vdelarosa@curapath.com).

To learn more about Curapath, please visit www.curapath.com

Elena Gallon
Polypeptide Therapeutic Solutions
+34 679 49 06 85
email us here
Visit us on social media:
LinkedIn

Media gallery